Resources Repository
-
ArticlePublication 2015Cost-Effectiveness & Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir & Ledipasvir in the U.S.
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic …
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic hepatitis C virus (HCV) infection compared to the old standard of care (oSOC). Using a microsimulation model based on HCV natural history, data from published literature, and a third-party payer perspective, the analysis considers treatment-naive and treatment-experienced HCV populations in the United States over a lifetime horizon. Sofosbuvir-based therapies are found to add 0.56 quality-adjusted life-years (QALYs) relative to oSOC,…
Microsimulation | North America | Infectious Diseases | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2015Clinical Role and Cost-Effectiveness of Long-Acting ART
Long-acting antiretroviral therapy (LA-ART) could potentially improve outcomes in particular for those HIV-infected individuals with …
Long-acting antiretroviral therapy (LA-ART) could potentially improve outcomes in particular for those HIV-infected individuals with poor daily ART adherence. In this study the clinical role and cost-effectiveness of 3 long-acting ART strategies (LA-ART for patients with multiple ART failures; second-line LA-ART for those failing first-line therapy; and first-line LA-ART for ART-naive patients) are compared to daily oral ART using a microsimulation model. The findings of this study showed that LA-ART could improve survival of…
Microsimulation | North America | Infectious Diseases | Cost-Effectiveness Analysis | Health/Medicine -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
North America | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2014HIV Cure Strategies: How Good Must They be to Improve on ART?
This article uses a microsimulation model to explore under what circumstances three HIV cure strategies …
This article uses a microsimulation model to explore under what circumstances three HIV cure strategies (gene therapy, chemotherapy and stem cell transplantation (SCT)) would improve efficacy, toxicity, cost and quality of life outcomes compared to current antiretroviral therapy (ART). Assuming a cost-effectiveness threshold of $100,000 per QALY, results show that gene therapy was cost-effective compared to ART with an efficacy of 10%, relapse rate of 0.5%/month, and cost of $54,000. Chemotherapy was cost-effective with an…
Microsimulation | North America | Infectious Diseases | Cost-Effectiveness Analysis | Health/Medicine -
ReviewPublication 2013Role of Health Economic Analyses in Vaccine Decision Making
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in …
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in the US, cost effectiveness became a topic of discussion when a vaccine was being considered for universal use by the US Advisory Committee on Immunization practices (ACIP). In 2008, the ACIP began using formal criteria for the presentation of such data and their inclusion in ACIP discussions. More recently, the U.S. Institute of Medicine has recommended that health economic considerations play a…
North America | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2010Empirically Evaluating Decision-Analytic Models
To augment model credibility, evaluation via comparison to independent, empirical studies is recommended. The authors …
To augment model credibility, evaluation via comparison to independent, empirical studies is recommended. The authors developed a structured reporting format for model evaluation and conducted a structured literature review to characterize current model evaluation recommendations and practices. As an illustration, they applied the reporting format to evaluate a microsimulation of human papillomavirus and cervical cancer. The model's outputs and uncertainty ranges were compared with multiple outcomes from a study of long-term progression from high-grade precancer…
Microsimulation | North America | Infectious Diseases | Calibration/Validation | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2009Cost-Effectiveness of HPV Vaccination and Cervical Cancer Screening in Women Aged 30+ Years in the U.S.
The objective of the study was to assess the health and economic outcomes of HPV …
The objective of the study was to assess the health and economic outcomes of HPV vaccination in older U.S. women. The authors conducted a cost-effectiveness analysis with an empirically calibrated model using data from published literature; interventions included HPV vaccination added to screening strategies that differ by test (cytology or HPV DNA testing), frequency, and start age versus screening alone.They found that in the context of annual or biennial screening, HPV vaccination of women aged…
Microsimulation | North America | Infectious Diseases | Cost-Effectiveness Analysis | Chronic Disease/Risk | Clinical Care | Economics/Finance | Health/Medicine | Science/Technology -
ArticlePublication 2009Cost Effectiveness Analysis of Including Boys in a HPV Vaccination Program in the U.S.
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a …
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a routine human papillomavirus (HPV) vaccination program for preadolescent girls. The analysis included girls and boys aged 12 years; interventions included HPV vaccination of girls alone and of girls and boys in the context of screening for cervical cancer. The authors found that with 75% vaccination coverage and an assumption of complete, lifelong vaccine efficacy, routine HPV vaccination of 12-year-old girls…
Microsimulation | North America | Infectious Diseases | Dynamic Transmission | Calibration/Validation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Clinical Care | Economics/Finance | Health/Medicine -
ArticlePublication 2008Health and Economic Implications of HPV Vaccination in the U.S.
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical …
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical carcinogenesis to compare the health and economic outcomes of vaccinating preadolescent girls in the US (at 12 years of age), and vaccinating older girls and women in catch-up programs (to 18, 21, or 26 years of age). The study also examined the health benefits of averting other HPV-16-related and HPV-18-related cancers, the prevention of HPV-6-related and HPV-11-related genital warts and…
Microsimulation | North America | Infectious Diseases | Dynamic Transmission | Calibration/Validation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Clinical Care | Economics/Finance | Health/Medicine | Science/Technology